Slashdot Mirror
Price-gouging Maker of EpiPen Literally Said That Critics Can Go Fuck Themselves (gizmodo.com)
Back in August of 2016, the pharmaceutical company Mylan came under fire for jacking up prices of the EpiPen from $57 in 2007 to roughly $600 in 2016. The public backlash has been significant. Gizmodo adds: But the chairman of Mylan has a message for any critics: Go fuck yourself. Well, at least that's what we think he said. The New York Times has a new article about the fact that prices for the live-saving allergy medication haven't actually come down since last year. And the article has a rather strange way of describing the attitude of Mylan chairman Robert Coury. This is how the New York Times describes Coury's reaction to critics of Mylan's price gouging: "Mr. Coury replied that he was untroubled. He raised both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, ought to go copulate with themselves. Critics in Congress and on Wall Street, he said, should do the same. And regulators at the Food and Drug Administration? They, too, deserved a round of anatomically challenging self-fulfillment."
The epipen isn't the only player in the market, its popularity is due to schools support for it, as an easy way to administer the drug. If it is too expensive the schools should consider a replacement. And have this guy just blame critics in the poor house with a stack of epipens that he will sell at a loss.
If something is so important that you feel the need to post it on the internet... It probably isn't that important.
You think that the government would be less bloated? We are talking about the government. They created the concept of ineffectual bloat and then expanded, enhanced and perfected it. The government home of the $50,000 hammer. No, private industry with a profit motive will always be more efficient than government bureaucrats with no motive at all for efficiency and service. Take a look at the deadly mess that is the VA and tell me single payer is better.
Are you talking about the bloat private companies invented to charge to the gov because they can get away with it? It's always going to be cheaper and better to have public services, if for nothing else no one is looking to profit off it and any extra money made goes back into the service or others. It's in private industry with a profit motive it's all but encouraged to cut service and increase price. If you truly think that's better you're deluded. I don't know about your VA but I'd be willing to bet most of it's problems will be caused by subcontracting to private companies.
Wanna buy a shirt?
https://www.redbubble.com/people/stealthfinger/shop?asc=u
There are varied degrees. I am allergic to bees. With most, I'll swell up and have some throat constriction. With a few, I'll have a reasonable amount of time to seek treatment. With a very small number, a single sting is enough to mean I need immediate treatment, or I will die. Most of the time, I won't need any treatment at all. I'll just have to calm down and ensure I keep breathing well enough.
If you're curious, I don't even bother carrying my shot kit. It is fairly unlikely that I will need it and there's usually one that I can access, if I have enough time.
"So long and thanks for all the fish."
My friend gave it to me as he was dying. It seemed very important to him that I have it.
If Slashdot were chemistry it would look like this:Cadaverine
Perhaps we should stick Mr. Coury's head in a beehive for a few minutes and then see if he can masturbate. Totally for science, of course!
The world's burning. Moped Jesus spotted on I50. Details at 11.
The readily available components for this - a one-dose vial of epinephrine and an appropriate syringe - costs less than $10, less than $5 if you shop around. People are reluctant to use those because it's more complex and cumbersome than an epipen, but they should. Especially backup doses.
And items like this the USA should just declare eminent domain and manufacture/distribute them at cost. This goes for any patented medicine not made available in sufficient quantity and at cost with not more than reasonable profit.